ALD00602
(–)-PSI Reagent
95%
別名:
(2S,3aS,6R,7aS)-3a-Methyl-2-((perfluorophenyl)thio)-6-(prop-1-en-2-yl)hexahydrobenzo[d][1,3,2]oxathiaphosphole 2-sulfide, (–)-Ψ, Phosphorus-Sulfur Incorporation Reagent
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C16H16F5OPS3
CAS番号:
分子量:
446.46
MDL number:
UNSPSC Code:
12352101
NACRES:
NA.22
Assay:
95%
Form:
powder or crystals
assay
95%
form
powder or crystals
mp
103-107 °C
SMILES string
Fc1c(c(c(c(c1F)F)S[P]2(=S)S[C@@]3([C@@H](O2)C[C@@H](CC3)C(=C)C)C)F)F
InChI
1S/C16H16F5OPS3/c1-7(2)8-4-5-16(3)9(6-8)22-23(24,26-16)25-15-13(20)11(18)10(17)12(19)14(15)21/h8-9H,1,4-6H2,2-3H3/t8-,9+,16+,23?/m1/s1
InChI key
YPYCUYPOHPPYAS-QSHUGKRNSA-N
Application
Air- and moisture-tolerant, this (-)-PSI Reagent was developed in the Baran lab for stereocontrolled synthesis of phosphorothioate oligonucleotides. The enantiomer, (+)-PSI Reagent, is also available (cat# ALD00604).
The PSI Reagents open access to thiophosphate-based nucleotide molecules with therapeutic promise as demonstrated by the Baran lab in the preparation of pure stereoisomers of cyclic dinucleotides (CDNs) and antisense oligonucleotides (ASOs).
Learn more about PI and PSI reagents
The PSI Reagents open access to thiophosphate-based nucleotide molecules with therapeutic promise as demonstrated by the Baran lab in the preparation of pure stereoisomers of cyclic dinucleotides (CDNs) and antisense oligonucleotides (ASOs).
Learn more about PI and PSI reagents
Legal Information
PCT/US2019/027256; U.S. Nonprovisional Patent Application #16/382,692
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
ALD00602-BULK: + ALD00602-VAR: + ALD00602-500MG: + ALD00602-1KG: + ALD00602-100G: + ALD00602-25G: + ALD00602-5G:
jan
Kyle W Knouse et al.
Science (New York, N.Y.), 361(6408), 1234-1238 (2018-08-04)
Phosphorothioate nucleotides have emerged as powerful pharmacological substitutes of their native phosphodiester analogs with important translational applications in antisense oligonucleotide (ASO) therapeutics and cyclic dinucleotide (CDN) synthesis. Stereocontrolled installation of this chiral motif has long been hampered by the systemic